BPC-157 + TB-500 Stack

The BPC-157 + TB-500 combination creates a powerful synergistic effect through complementary mechanisms of action. BPC-157 works primarily by promoting angiogenesis (blood vessel formation) and appears to activate the FAK-paxillin pathway, which supports cellular adhesion and migration. Studies suggest it may also influence the nitric oxide system and VEGF (vascular endothelial growth factor) expression.

TB-500, meanwhile, contains the active sequence of Thymosin β4, which promotes cellular migration through actin regulation. Research demonstrates that TB-500 enhances wound healing by increasing collagen deposition and reducing inflammation. It appears to work through the PINCH-1 pathway and may influence stem cell migration to injury sites.

Together, these mechanisms create a comprehensive recovery environment. Whilst BPC-157 focuses on vascular support and gastric protection, TB-500 addresses inflammation and tissue remodelling. This combination may be particularly effective because BPC-157's vascular effects can enhance the delivery of TB-500 to target tissues.

The synergy extends to their anti-inflammatory properties. Both peptides appear to modulate inflammatory cascades, but through different pathways, potentially providing more comprehensive inflammation control than either peptide alone. Early research also suggests both peptides may support neurological recovery, making this stack attractive for those dealing with various types of tissue damage.

This complementary action profile makes the BPC-157 + TB-500 stack one of the most logical peptide combinations for recovery-focused protocols.

BPC-157 Dosing:

• Amount: 250-500mcg per injection
• Frequency: Once daily, preferably morning on empty stomach
• Injection site: Subcutaneous, rotate between abdomen, thighs, or near injury site if applicable
• Cycle length: 4-8 weeks, followed by 4-week break

TB-500 Dosing:

• Amount: 2-2.5mg per injection (loading phase), then 1-2mg (maintenance)
• Frequency: Twice weekly for 4 weeks (loading), then once weekly
• Injection site: Subcutaneous, can be same area as BPC-157 but different injection point
• Cycle length: 8-12 weeks total

Timing Protocol: Administer BPC-157 daily upon waking, 30 minutes before breakfast. TB-500 can be taken on the same days as BPC-157 but space injections by at least 30 minutes. Many users prefer TB-500 in the evening.

Reconstitution: Both peptides should be reconstituted with bacteriostatic water. See our reconstitution guide for detailed mixing instructions. Store reconstituted peptides in refrigerator and use within 30 days.

Injection Technique: Use insulin syringes (29-31 gauge) for subcutaneous injection. Rotate injection sites to prevent tissue irritation. Clean injection site with alcohol before administering.

Cycle Structure:

• Weeks 1-4: BPC-157 daily + TB-500 twice weekly (loading)
• Weeks 5-8: BPC-157 daily + TB-500 once weekly (maintenance)
• Weeks 9-12: 4-week complete break before considering another cycle

Weeks 1-2: Initial effects typically begin within the first week. Users often report improved sleep quality and reduced general soreness. Some notice faster recovery between training sessions and reduced joint stiffness upon waking.

Weeks 3-4: More pronounced benefits emerge as tissue levels stabilise. Enhanced workout recovery becomes more apparent, with reduced delayed onset muscle soreness (DOMS). Users frequently report improved gut health and digestion, particularly with BPC-157's gastric protective effects.

Month 2: Peak benefits are typically observed during this period. Chronic niggles and minor injuries may show improvement. Enhanced overall recovery capacity becomes evident, with users able to maintain higher training volumes. Sleep quality and general wellbeing often reach optimal levels.

Month 3+: Long-term benefits include sustained recovery improvements and potential resolution of minor chronic issues. Many users report maintained benefits for several weeks after completing their cycle, suggesting lasting tissue improvements. However, benefits typically begin to diminish without continued use, making strategic cycling important for sustained results.

Both BPC-157 and TB-500 are generally well-tolerated, with most users reporting minimal side effects. Common mild effects include temporary injection site redness or minor irritation, which typically resolves within hours.

Potential Side Effects:

• Fatigue or lethargy (particularly in first few days)
• Mild headaches during initial adjustment period
• Temporary changes in appetite
• Slight water retention (more common with TB-500)
• Injection site reactions

Contraindications: Avoid this stack if you have active cancer, as both peptides may theoretically promote cell growth. Pregnant or breastfeeding women should not use these peptides. Those with bleeding disorders should exercise caution due to potential effects on blood clotting.

Who Should Avoid: Individuals under 21, those with serious medical conditions, or anyone taking blood thinning medications should consult healthcare providers before use. People with known allergies to either peptide should obviously avoid this combination.

UK Legal Considerations: Both peptides exist in a regulatory grey area in the UK. Whilst not illegal to possess for research purposes, they cannot be sold for human consumption. Review our UK peptide legality guide for current regulations and compliance considerations.